Insiders who purchased Larimar Therapeutics, Inc. (NASDAQ:LRMR) earlier this year lose an additional US$351k as the stock sinks to US$2.56

By
Simply Wall St
Published
May 13, 2022
NasdaqGM:LRMR
Source: Shutterstock

The recent price decline of 31% in Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) stock may have disappointed insiders who bought US$496k worth of shares at an average price of US$8.75 in the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$145k which is not ideal.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Larimar Therapeutics

The Last 12 Months Of Insider Transactions At Larimar Therapeutics

Over the last year, we can see that the biggest insider purchase was by Independent Director Thomas Hamilton for US$496k worth of shares, at about US$8.75 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$2.56). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Thomas Hamilton was the only individual insider to buy shares in the last twelve months.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqGM:LRMR Insider Trading Volume May 13th 2022

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Does Larimar Therapeutics Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data isn't picking up on much insider ownership at Larimar Therapeutics, though insiders do hold about US$412k worth of shares. We might be missing something but that seems like very low insider ownership.

So What Does This Data Suggest About Larimar Therapeutics Insiders?

It doesn't really mean much that no insider has traded Larimar Therapeutics shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Larimar Therapeutics stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 6 warning signs for Larimar Therapeutics (2 can't be ignored) you should be aware of.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.